Chester County News and Community Website
MALVERN, PA — Baudax Bio, Inc. (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, announced a virtual poster presentation highlighting ANJESO™ (meloxicam) injection data at Digestive …
Read More MALVERN, PA — Baudax Bio, Inc. (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, announced two virtual poster presentations highlighting new ANJESO™ (meloxicam) injection data at …
Read More
MALVERN, PA — Baudax Bio, Inc. (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, announced that ANJESO™ (meloxicam) injection, the only 24-hour, intravenous (IV) COX-2 preferential …
Read More
MALVERN, PA — Recro Pharma, Inc. (NASDAQ: REPH), a pharmaceutical company with a high-performing, revenue-generating contract development and manufacturing (CDMO) segment and an Acute Care segment, reported financial results for the three and …
Read More
MALVERN, PA — Recro Pharma, Inc. (NASDAQ: REPH), a revenue-generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care settings, announced the publication of clinical data from its Phase III …
Read More
MALVERN, PA — Recro Pharma, Inc. (NASDAQ: REPH), a revenue-generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, reported financial results for the fourth quarter and year …
Read More
MALVERN, PA — Recro Pharma, Inc. (NASDAQ: REPH), a revenue-generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, announced an amendment to its global licensing agreement with Alkermes …
Read More
MALVERN, PA — Recro Pharma, Inc. (NASDAQ: REPH), a revenue-generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today provided a regulatory update following receipt of the …
Read More
MALVERN, PA — Recro Pharma, Inc. (NASDAQ: REPH), a revenue-generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, announced the publication of previously reported Phase III …
Read More
PAOLI, PA — Sedor Pharmaceuticals, LLC (Sedor) and Los Altos Pharmaceuticals, Inc. (Los Altos) announced that Sedor has granted Los Altos an exclusive license for Captisol-enabled™ (CE) Meloxicam for the People’s Republic of China (PRC). …
Read More